HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

Histone deacetylase (HDAC) inhibitors are emergent cancer drugs. HR23B is a candidate cancer biomarker identified in a genome-wide loss-of-function screen which influences sensitivity to HDAC inhibitors. Because HDAC inhibitors have found clinical utility in cutaneous T-cell lymphoma (CTCL), we eval...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Khan, Omar, Fotheringham, Susan, Wood, Victoria, Stimson, Lindsay, Zhang, Chunlei, Pezzella, Francesco, Duvic, Madeleine, Kerr, David J., La Thangue, Nicholas B.
Natura: Artigo
Lingua:Inglês
Pubblicazione: National Academy of Sciences 2010
Soggetti:
Biological Sciences
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2851972/
https://ncbi.nlm.nih.gov/pubmed/20308564
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0913912107
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi